| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 423.56% | Goldman Sachs | $1.75 → $1.5 | Maintains | Buy |
| 11/09/2023 | 39.62% | Piper Sandler | $1 → $0.4 | Maintains | Neutral |
| 11/09/2023 | 423.56% | Goldman Sachs | $1.75 → $1.5 | Maintains | Buy |
| 11/09/2023 | 1505.58% | Morgan Stanley | $5 → $4.6 | Maintains | Equal-Weight |
| 11/01/2023 | 249.04% | Stifel | $3 → $1 | Maintains | Buy |
| 08/11/2023 | 510.82% | Goldman Sachs | $2 → $1.75 | Maintains | Buy |
| 08/10/2023 | 510.82% | Goldman Sachs | $2 → $1.75 | Maintains | Buy |
| 08/10/2023 | 249.04% | Piper Sandler | $2.5 → $1 | Downgrades | Overweight → Neutral |
| 05/11/2023 | 598.08% | Goldman Sachs | $2.25 → $2 | Maintains | Buy |
| 05/10/2023 | 1645.2% | Morgan Stanley | $5.5 → $5 | Maintains | Equal-Weight |
| 03/13/2023 | 685.34% | Goldman Sachs | $2.5 → $2.25 | Maintains | Buy |
| 03/09/2023 | 1819.72% | Morgan Stanley | $5.75 → $5.5 | Maintains | Equal-Weight |
| 01/06/2023 | 1906.98% | Morgan Stanley | $6.35 → $5.75 | Maintains | Equal-Weight |
| 11/10/2022 | 2116.4% | Morgan Stanley | $6.9 → $6.35 | Maintains | Equal-Weight |
| 10/04/2022 | 947.12% | Stifel | $4 → $3 | Maintains | Buy |
| 08/11/2022 | 1645.2% | Piper Sandler | $7 → $5 | Maintains | Overweight |
| 06/17/2022 | 1994.24% | Stifel | $10 → $6 | Maintains | Buy |
| 05/11/2022 | 2343.28% | Piper Sandler | $12 → $7 | Maintains | Overweight |
| 03/24/2022 | 3390.4% | Goldman Sachs | $30 → $10 | Maintains | Buy |
| 03/24/2022 | 4088.48% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 01/31/2022 | 2308.38% | Morgan Stanley | → $6.9 | Initiates Coverage On | → Equal-Weight |
| 11/23/2021 | 5484.64% | Stifel | → $16 | Initiates Coverage On | → Buy |
| 11/23/2021 | 5135.6% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 11/23/2021 | 10371.2% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 11/23/2021 | 5833.68% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
What is the target price for Sonendo (SONX)?
The latest price target for Sonendo (NYSE: SONX) was reported by Goldman Sachs on November 10, 2023. The analyst firm set a price target for $1.50 expecting SONX to rise to within 12 months (a possible 423.56% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sonendo (SONX)?
The latest analyst rating for Sonendo (NYSE: SONX) was provided by Goldman Sachs, and Sonendo maintained their buy rating.
When is the next analyst rating going to be posted or updated for Sonendo (SONX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonendo, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonendo was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Sonendo (SONX) correct?
While ratings are subjective and will change, the latest Sonendo (SONX) rating was a maintained with a price target of $1.75 to $1.50. The current price Sonendo (SONX) is trading at is $0.29, which is out of the analyst's predicted range.